ArticleRSC advances2025
Application of radiotherapy-preexcited gambogic acid dual targeting nanoparticles in colorectal cancer.
Liuqi Sang, Qun Zhang, Zixin Liang, Xinyi Xu, Xueying Bai, Ning Wang, Xingzhi Han, Li Li, Jing Hu, Xiaoping Qian
Abstract read
In one paragraphArticle in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Qun ZhangComprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University, Clinical Cancer Institute of Nanjing University Nanjing 210008 China.
Zixin LiangDepartment of Oncology, Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine 321 Zhongshan Road Nanjing Jiangsu 210008 China xiaopingqian@nju.edu.cn doctorhujing@163.com +86-25-68182342 +86-13951743162 +86-13057668736.ORCID https://orcid.org/0009-0004-2334-9536 Xinyi XuDepartment of Oncology, Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine 321 Zhongshan Road Nanjing Jiangsu 210008 China xiaopingqian@nju.edu.cn doctorhujing@163.com +86-25-68182342 +86-13951743162 +86-13057668736.
Xueying BaiDepartment of Oncology, Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine 321 Zhongshan Road Nanjing Jiangsu 210008 China xiaopingqian@nju.edu.cn doctorhujing@163.com +86-25-68182342 +86-13951743162 +86-13057668736.
Ning WangDepartment of Oncology, Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine 321 Zhongshan Road Nanjing Jiangsu 210008 China xiaopingqian@nju.edu.cn doctorhujing@163.com +86-25-68182342 +86-13951743162 +86-13057668736.
Xingzhi HanComprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University, Clinical Cancer Institute of Nanjing University Nanjing 210008 China.
Li LiComprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University, Clinical Cancer Institute of Nanjing University Nanjing 210008 China.
Jing HuDepartment of Oncology, Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine 321 Zhongshan Road Nanjing Jiangsu 210008 China xiaopingqian@nju.edu.cn doctorhujing@163.com +86-25-68182342 +86-13951743162 +86-13057668736.
Xiaoping QianThe Comprehensive Cancer Center, Nanjing Drum Tower Hospital Clinical College of Xuzhou Medical University Nanjing 210008 China.
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Delivering anti-tumor drugs to the correct location is an important strategy for improving tumor treatment efficacy and reducing side effects. To this end, this study developed a P-selectin-targeted drug delivery platform, where fucoidan-modified PLGA nanoparticles were loaded with the anti-tumor drug gambogic acid (GA) to form a novel nanoparticle, Fucoidan-PLGA/GA NPs (FPG). Fucoidan serves as a natural hydrophilic shell, enabling specific dual-targeting by binding to P-selectin overexpressed on tumor vascular endothelial cells and tumor cells, allowing FPG to cross the vascular barrier and reach the tumor tissue.
Identifiers
PMID41356714
PMCPMC12679429
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390